Level 1: eLearning

ESMIT Live Webinar series

Easily accessible from the comfort of your own home – Get the best of ESMIT education without travelling!

Live webinars are condensed pieces of live, high-quality education which include theoretical presentations, case-based teachings, and a lot of interaction between our facilitators and our participants.

Through this series of free live webinars, experts in the field of nuclear medicine will share their knowledge about various topics in an interactive online setting accessible from all over the world.

  • All webinars are written and facilitated in English.
  • Each live webinar is limited to 250 participants.
  • After the live event has taken place, the recording will be accessible for free on our eLearning platform. You can access the eLearning materials by logging in with your personal username and password or easily creating a new confidential account.
  • Participants of the live webinar series will receive CME credits.

 

 

Upcoming ESMIT Live Webinars 

 

You can find the confirmed 2021 ESMIT webinar offer below. The registrations will open soon.


12.03.2021 - Tracers targeting FAP for PET imaging and therapy: Premises and future promises

March 12, 2021 – 13:30 (CET)

 
Speaker: Thomas Lindner
Moderator: Filippo Lodi
Target audience: Radiopharmacists, Nuclear medicine physicians, residents
 

Content

This webinar will focus on targeting the stroma in the tumor microenvironment as an attractive goal for diagnostic imaging and therapy. The tumor stroma commonly contributes for > 90% of the tumor mass in carcinomas characterized by a desmoplastic reaction, such as breast, colon, and pancreatic carcinomas. The tumor is dependent on the reactive stroma for survival and growth signals, as well as the nutritional support required for maintenance of the primary mass. Additionally, the stroma is able to contribute and to drive the progression of cancerous cells into a highly aggressive and metastatic phenotype. Fibroblasts, which are the major components of tumor stroma, are called cancer-associated fibroblasts (CAFs). CAFs are perpetually activated and have common properties distinct from normal fibroblasts like the expression of FAP (fibroblast activation protein), a type II transmembrane serine protease which plays multiple biologic roles in cancer and it is associated with a poor prognosis in a variety of tumors. Targeting FAP for imaging and endoradiotherapy can be considered as a promising strategy in Nuclear Medicine for the detection and treatment of malignant tumors. Several small-molecule inhibitors of FAP were developed and labeled with PET and therapeutic radioisotopes for theranostics approach. The webinar will discuss why FAP is an attractive target for molecular imaging and therapy showing the available tracers as well. It will also provide the interesting clinical applications along with the future directions in this regard.

 

Learning Objectives

  • To understand why FAP is an attractive target for the development of tracers for imaging and therapy
  • To provide an overview on the different tracers targeting FAP for PET imaging and for therapy
  • To show the interesting current clinical approaches and the future applications of these tracers in oncology

 

CME Credits 

An application has been made to the UEMS EACCME for CME accreditation of this event.

 

Suggested Readings

  • Lindner T. et al. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J Nucl Med 2018; 59:1415–1422
  • Loktev A, et al. Development of novel FAP-targeted radiotracers with improved tumor retention. J Nucl Med 2019;60(10):1421-1429
  • Kratochwil C, et al. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019; 60(6):801-805
  • Meyer C., et al. Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients; J Nucl Med 2020; 61:1171–1177
  • Giesel F. L., et al. FAPI-74 PET/CT Using Either 18F-AlF or Cold-kit 68Ga-labeling: Biodistribution, Radiation Dosimetry and Tumor Delineation in Lung Cancer Patients. J Nucl Med. 2020 Jun 26. Online ahead of print.

 


26.03.2021 - Theranostic application for radionuclide treatment

March 26, 2021 – 13:30 (CET)

 
Speaker: Tessa Brabander
  Christophe Deroose
  Uwe Haberkorn
Moderator: Patrick Pilkington
Target audience: Nuclear Medicine Physicians and Residents / Oncologists / Radiation Oncologists / All involved in the
field of diagnosis and treatment of diferent tumors.
 

Content

Theranostics is the epitome of personalised medicine. During this webinar,
participants will learn the basic concepts and principles of theranostic treatment. Our experienced speakers will cover the most widely used biomarkers imaged on PET/CT and SPECT/CT with their corresponding alpha or beta-emitting radionuclide pair, and how to appropriately select patients which will most likely benefit from it use. All this with the help of specially selected clinical cases. Also, at the end of the webinar, we will have a Q&A round to address all your doubts and thoughts.

 

Learning objectives

  • Introduce the concept and basic principles of Theranostics.
  • To cover the most widely used and available specific tumour biomarkers imaged on PET/CT and SPECT/CT with their corresponding alpha or beta-emitting radionuclide pair.
  • How to select patients that will benefit from theranostic treatment.

 

CME Credits

An application has been made to the UEMS EACCME for CME accreditation of this event.


09.04.2021 - The additional value of hybrid imaging in coronary artery disease

April 9, 2021 – 13:30 (CET)

 
Speaker: Samia Massalha
Eliana Reyes
Moderator: Christoph Rischpler
Target audience: Nuclear medicine physicians, residents in nuclear medicine, imaging cardiologists, radiologists or residents in radiology.
 

 

Content

Today, hybrid imaging is an integral part of cardiovascular imaging in nuclear medicine. In this webinar, we will discuss the additional value of morphological imaging in the diagnosis of coronary artery disease. It will be discussed what influence other parameters or modalities such as calcium score or CT angiography have on the interpretation of myocardial perfusion imaging and how this affects the diagnosis.

 

Learning Objectives

The aim of this course is to understand

  • what patients benefit most from hybrid imaging
  • how hybrid imaging (e.g. acquisition of calcium score and CTA) is performed
  • how the acquired images and parameters are interpreted and reported to the referring clinician. Reporting the extra cardiac findings and its impact.
  • and what influence these parameters have on the diagnosis of coronary artery disease.

 

CME Credits

An application has been made to the UEMS EACCME for CME accreditation of this event.

 

Suggested readings

Online material at nedus.netkey.at:

  • ESMIT 2020 webinar: PET MPI – Tracers, Equipment, Protocols, Flow Quantification, Viability
  • ESMIT 2020 webinar: SPECT-MPI: Protocols, Pearls and Pitfalls
  • ESMIT 2020 webinar: Principles and Indications for Stress MPS
  • Autumn School 2019 – Cardio Track PeT 2 – Essential of MPI (SPECT): stress and pharmacological protocols overview
  • Autumn School 2019 – Cardio Track PeT 1 – Images analysis and semi-quantification of gated SPECT and SPECT-CT

Readings:

  • EANM procedural guidelines for PET/CT quantitative myocardial perfusion imaging
    Sciagra et al. EJNMMI 2020
  • Combined evaluation of regional coronary artery calcium and myocardial perfusion by 82Rb PET/CT in the identification of obstructive coronary artery disease, Zampella et al. EJNMMI 2018
  • Prognostic value of atherosclerotic burden and coronary vascular function in patients with suspected coronary artery disease, Assante et al. EJNMMI 2017
  • EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision
    Verberne et al. EJNMMI 2015
  • Very high coronary artery calcium score with normal myocardial perfusion SPECT imaging is associated with a moderate incidence of severe coronary artery disease Yuoness et al. EJNMMI 2015
  • Cardiac hybrid imaging Gaemperli et al. EJNMMI 2014
    Integrated SPECT/CT for assessment of haemodynamically significant coronary artery lesions in patients with acute coronary syndrome
    Rischpler et al. EJNMMI 2011


16.04.2021 - Radiobiology in practice

April 16, 2021 – 13:30 (CET)

 
Speaker: An Aerts
Nicolas Varmenot
Moderator: Chiara M. Grana
Target audience: Physicists, Physicians, Technologists
 

 

Content

Radiobiology is a branch of biology devoted to the study of biological effects of ionizing radiation on living organisms. We can speak about radiobiology in different clinical and research setting of Nuclear Medicine: dosimetry, preclinical and translational science, oncology and radiation protection.
By this webinar we will try to better understand the importance of this topic in different fields in order to reach one target: we need always more efficient and safer radiopharmaceuticals for personalized cancer diagnosis and treatment.

 

Learning Objectives

The aim of this course will be to understand the importance of radiobiology in cancer diagnosis and therapy.

 

CME Credits

An application has been made to the UEMS EACCME for CME accreditation of this event.


23.04.2021 - Diuretic renography in children - EANM & SNMMI procedural guidelines

April 23, 2021 – 13:30 (CET)

 
Speaker: Zvi Bar-Server
Ana Isabel Santos
Moderator: Lars Kurch
Target audience: This course addresses everyone who is interested in the performance of diuretic renography in childrens. However, it fits best for physicians in training with basic / intermediate knowledge and clincial experience of 1-3 years.
 

 

Content

Based on the latest guidelines published we will review main recommendations and specificities of how to perform diuretic renography scans in children. Attention will be drawn to different clinical contexts, avaiable radiopharmaceuticals, patient preparation, different acquisition protocols as well as tricks and problems of data processing. A further important topic will be the interpretation of the scans as well as performing an adequate reporting and a clinical audit. Cases and case discussions will be used to transfer the gained knowledge into clinical practice. Pariticipants are kindly invited to share their working experience and to spark off discussions if necessary.

 

Learning Objectives

The main learning objectives are to understand referrals, good practices for the performance of the exam, main pitfalls and how to improve the clinical impact of the exam.

 

CME Credits

An application has been made to the UEMS EACCME for CME accreditation of this event.

 

Suggested readings

  • Massoud Majd et al., “The SNMMI and EANM Procedural Guidelines for Diuresis Renography in Infants and Children.,” J Nucl Med 59, no. 10 (October 2018): 1636–40, doi:10.2967/jnumed.118.215921.


07.05.2021 - Quantification in PET: status quo, future direction and related myths

May 7, 2021 – 13:30 (CET)

 
Speaker: Ian Armstrong
Wolfgang Weber
Moderator: Stephan Nekolla
Target audience: Physicists, Physicians, Technologists
 

 

Content

Although quantification in PET imaging is one of is cornerstones and key selling points, so to speak, there is quite a variability in this implementation in our field. This webinar discusses the technical requirements, the physiological assumptions and the future directions from both the physicist’s as well as the clinician’s perspective. Emphasis will be given on an integration into efficient workflows and on the harmonization of quantification in hybrid imaging .

 

CME Credits

An application has been made to the UEMS EACCME for CME accreditation of this event.


21.05.2021 - Malignant versus benign bone tumors : a 10-point guide to survival

May 21, 2021 – 13:30 (CET)

 
Speaker: David Morland
Target audience: Nuclear medicine residents (Level 2 – Level 3) and physicians
 

Content

The distinction between benign and malignant bone tumors presents a twofold challenge in nuclear medicine: not ignoring an aggressive lesion and delaying the initiation of treatment, but also knowing when to stop unnecessary or even invasive investigations in benign lesions. In this webinar, we will review the 10 most important characteristics of bone lesions to be taken into account in the analysis: age, pain, location, lytic or sclerotic phenotype, margins, evolutivity, periosteal reaction, soft tissue extension, joint extension, distribution. The presentation will combine theoretical points with practical examples.

 

Learning Objectives

The aim of this course is to learn how to distinguish benign from malignant bone tumors.

 

CME Credits

An application has been made to the UEMS EACCME for CME accreditation of this event.

 

Suggested readings

  • Madewell et al. Radiologic and pathologic analysis of solitary bone lesions. Radiol Clin North Am 1981;
  • Caracciolo J et al. A modified Lodwick-Madewell Grading System for the evaluation of lytic bone Lesions. AJR 2016;20:W1-W7


28.05.2021 - Hot topics in nuclear medicine data processing: radiomics and artificial intelligence

May 28, 2021 – 13:30 (CET)

 
Speaker: Chiara M. Grana
Dimitris Visvikis
Moderator: Stephan Nekolla
Target audience: Physicists, Physicians, Technologists
 

 

Content

The evolution of machine learning approaches with the introduction of deep learning techniques, has led to an exponential increase in the use of Artificial Intelligence (AI) in a variety of application areas, including the healthcare field. Within this context, AI has been introduced at different steps of medical imaging, covering the simulation of imaging devices, image formation including tomographic reconstruction and image related corrections to image processing for the subsequent exploitation of reconstructed images (image segmentation, harmonisation, radiomics analysis).
Starting from the request coming for the clinician with some examples of unmet needs, the webinar will proceed with latest advances in the field of NM image processing and some potential clinical endpoints.

 

Learning Objectives

The aim of this course will be to learn some possible answer to clinical unmet needs by radiomics and artificial intelligence.

 

CME Credits

An application has been made to the UEMS EACCME for CME accreditation of this event.

 

Suggested readings

CME13 EANM 2020


11.06.2021 - Molecular imaging in Parkinson's Disease

June 11, 2021 – 13:30 (CET)

 
Speaker: Elsmarieke van de Giessen
Moderator: Diego Cecchin
Target audience: Nuclear medicine physicians (in training), neuroradiologists, neurologists
 

 

Content

This live webinar on molecular imaging in Parkinson’s disease will offer a comprehensive overview of the theoretical background and practical evidence-based use of molecular imaging methods in Parkinson’s disease. It will primarily focus on clinically applied imaging methods of the dopaminergic system and how these relate to disease stages and symptoms. Besides, it will also shortly touch on imaging in atypical parkinsonisms. After the theoretical background several clinical cases will be discussed.

 

Learning Objectives

Learn more about the clinical presentation and neuropathology of Parkinson’s disease; Understand when to use which imaging method in parkinsonian syndromes; Learn how to acquire and interpret dopaminergic imaging (in particular dopamine transporter imaging).

 

CME Credits

An application has been made to the UEMS EACCME for CME accreditation of this event.

 

Suggested Readings

  • Am J Neuroradiol. 2015 The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 1. http://www.ajnr.org/content/36/2/229.long;
  • EANM webinar on Molecular basics of radiotracers for neuroimaging: radiotracers for parkinsonian syndromes by prof. Dr. I. Penuelas


 

Past ESMIT Live Webinars 

The recordings of the following webinars are available on the ESMIT eLearning Platform. Please note that CME credit may be earned for live webinars only. The archived versions of our webinars are not eligible for CME credit.


FDG PET and Structural MRI in Alzheimer and Dementia

June 10, 2020 – 12:00 (CEST)

 
Speaker: Diego Cecchin
Moderator: Elsmarieke van de Giessen
Target audience: Nuclear medicine physicians, residents, (neuro)radiologists
 

Content

This webinar will show typical 18F-FDG patterns of brain hypometabolism in the context of neurodegenerative disease and in particular regarding Alzheimer disease (AD) and fronto-temporal dementia (FTD). Moreover the talk will discuss main structural (MRI) alterations in neurodegeneration with particular attention to AD and FTD. Common (combined or not) hypometabolism and structural alterations will be presented using clinical 18F-FDG PET/MR cases. Finally proteinopaties concerning AD and FTD will be briefly discussed.

 

Learning objectives

  • Recognize common structural signs of neurodegeneration in MRI
  • Recognize common patterns of hypometabolism in 18FDG PET in AD and FTD
  • Understand which proteinopaty underlie AD and FTD

 

Suggested readings

  • A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers.
    Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, Petersen RC, Scheltens P, Sperling RA, Dubois B.Neurology. 2016 Aug 2;87(5):539-47. doi:10.1212/WNL.0000000000002923. Epub 2016 Jul 1.
    PMID: 27371494
  • Alzheimer’s disease.
    Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM.Lancet. 2016 Jul 30;388(10043):505-17.
    doi: 10.1016/S0140-6736(15)01124-1. Epub 2016 Feb 24.
    PMID: 26921134 Review.
  • FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease.
    Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, DeCarli CS, Turner RS, Koeppe RA, Higdon R, Minoshima S.Brain. 2007 Oct;130(Pt 10):2616-35.
    doi: 10.1093/brain/awm177. Epub 2007 Aug 18.
    PMID: 17704526


Principles and Indications for Stress MPS

June 10, 2020 – 14:00 (CEST)

 
Speakers: Alessia Gimelli
Eliana Reyes
Moderator: Christoph Rischpler
 

Content

This webinar introduces the basic principles that govern the clinical applications of stress MPS. The indications for MPS are discussed in the context of contemporary imaging technology and protocols, including the use of solid-state gamma-camera systems, the practicalities of regadenoson stress, and the added value of quantitative myocardial perfusion

 

Learning objectives

At the end of this webinar, participants should be able to:

  • Understand the principles underlying the use of MPS for the assessment of coronary artery disease
  • Appreciate the current indications for stress MPS
  • Become familiar with imaging & stress MPS protocols and their importance in clinical practice and service delivery standardisation
  • Recognise the effect of the most advances in stress MPS on clinical practice


Pitfalls and Artefacts in Prostate Cancer PET Imaging

June 12, 2020 – 14:00 (CEST)

 
Speaker: Paolo Castellucci
Moderators: Francesco Ceci
Patrick Pilkington
Target audience: Nuclear medicine physicians, urologist, radiation oncologist, residents
 

Content

In this live webinar we discuss pitfalls, different biodistribution and artefacts for PET/CT imaging in Pca. The lecture will focus on 68Ga-PSMA and 18F-PSMA PET and Fluciclovine PET. Clinical cases will be provided to support the lecture.

 

Learning objectives

  • To understand the different biodistribution among different PSMA variants
  • To understand possible sources of pitfall in PSMA imaging, both considering false positive and false negative findings
  • To introduce the basic concepts and the most common pitfalls in Fluciclovine PET

 

Suggested readings

  • Sheikhbahaei S,  et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44(12):2117-36. 39.
  • Rischpler C,  et al. 68Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging. Journal of Nuclear Medicine. 2018;59(9):1406-11.
  • Rauscher I, et al. Matched-pair comparison of (68)Ga-PSMA-11 and (18)F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J Nucl Med. 2019.
  • Nanni C, et al. [18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging-version 1.0. Eur J Nucl Med Mol Imaging. 2020;47(3):579‐591


Molecular Imaging in Dementia with Parkinsonism

July 9, 2020 – 12:00 (CEST)

 
Speaker: Silvia Morbelli
Moderator: Elsmarieke van de Giessen
Target audience: Nuclear medicine physicians, residents, (neuro)radiologists
 

Content

The talk will discuss the clinical use of brain PET and SPECT in Parkinson’s disease (PD) and atypical parkinsonisms associated with dementia. Both the clinical Utility Molecular Imaging in facilitating the differential diagnosis of common forms of parkinsonism as well as its role in the risk stratification of these patients. Accordingly studies on dementia with lewy bodies (DLB), PD, progressive supranuclear palsy (PSP) syndromes, and corticobasal syndrome (CBS) we’ll be discussed. Aspects related to the role of brain PET and SPECT in prodromal stages of disease will be coverd.

 

Learning objectives

  • To learn about the clinical utility of  FDG-PET and DAT SPECT  to support the diagnosis of parkinsonian syndromes associated with dementia
  • To understand the role of molecular imaging in predicting the risk of convension to dementia in patients with parkinsonism and in particular in PD patients.
  • To appreciate the added value of molecular imaging in prodromal stages of DLB and PD

 

Suggested readings

  • Nobili F, Arbizu J, Bouwman F, Drzezga A, Filippi M, Nestor P, et al. EAN-EANM recommendations for the use of brain 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol. 20181
  • Walker Z, Gandolfo F, Orini S, Garibotto V, Agosta F, Arbizu J, Bouwman F, Drzezga A, Nestor P, Boccardi M, Altomare D, Festari C, Nobili F; EANM-EAN Task Force for the recommendation of FDG PET for Dementing Neurodegenerative Disorders. Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1534-1545
  • KA. Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies. J Neural Transm. 2018;125(4):615–650. doi: 10.1007/s00702-017-1821-9
  • Research criteria for the diagnosis of prodromal dementia with Lewy bodies. McKeith IG, Ferman TJ, et al ; prodromal DLB Diagnostic Study Group. Neurology. 2020 Apr 28;94(17):743-755.
  • Morbelli, S., Esposito, G., Arbizu, J. et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes


SPECT-MPI: Protocols, Pearls and Pitfalls

July 9, 2020 – 14:00 (CEST)

 
Speakers: Antti Saraste
Fabien Hyafil
Moderator: Christoph Rischpler
Target audience: Nuclear medicine physicians, cardiologists, physicists, radiopharmacists
 

 

Content

  • Implementing gated SPECT
  • CAD diagnosis SPECT/CT
  • Viability detection SPECT
  • Artifacts
  • Challenges in MPI: pearls and pitfalls

 

Learning objectives

The aim of this webinar will be to give an overview on how to perform, analyze and write reports for SPECT-MPI.


How to report PSMA PET in Prostate Cancer. An Introduction to E-PSMA: The EANM standardized Reporting Guidelines v1.0 for PSMA PET/CT

July 10, 2020 – 14:00 (CEST)

 
Speaker: Francesco Ceci
Moderator: Patrick Pilkington
Target audience: Nuclear medicine physicians, urologists, radiation oncologists, residents
 

Content

This live webinar will discuss the standardization of the clinical report for PSMA PET in Prostate Cancer, in according to the most recent guidelines released by the EANM.

 

Learning objectives

This lecture will have as main objective to provide an overview about the new guidelines for reporting PSMA PET as suggested by the EANM. The audience will be introduced to the structured report for PSMA PET and will understand how to provide a report in accordance to EANM guidelines. Finally, hints and tips will be given regarding how to avoid common mistakes in PSMA PET images reading and how to interpret the most common findings that represent potential pitfalls.

 

Suggested readings

  • E-PSMA: The EANM standardized reporting guidelines v1.0 for PSMA PET/CT. Eur J Nucl Med Mol Imaging. 2020. [Under Review].
  • Eiber M, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT [published correction appears in J Nucl Med. 2018 Jun;59(6):992]. J Nucl Med. 2018;59(3):469‐478.
  • Ceci, F., Fanti, S. Standardisation of PSMA images interpretation: why do we need it?. Clin Transl Imaging 6, 331–333 (2018). https://doi.org/10.1007/s40336-018-0301-z.


Amyloid PET in Dementia

September 10, 2020 – 12:00 (CEST)

 
Speaker: Henryk Barthel
Moderator: Elsmarieke van de Giessen
Target audience: Nuclear medicine physicians, residents, (neuro)radiologists

Content

This webinar will discuss the available tracers to image amyloid pathology by PET, and the respective image analysis techniques. It will also provide the current clinical indications for amyloid imaging, together with future trends in this regard. Also, some amyloid PET imaging cases will be discussed.

 

Learning objectives

The aim of this webinar is

  • To provide an overview on the different amyloid PET tracers/respective analysis rules
  • To teach current appropriate use criteria for amyloid PET imaging
  • To increase amyloid PET reading confidence

 

Faculty

  • Univ.-Prof. Dr. med. Henryk Barthel – Department of Nuclear Medicine, University of Leipzig/Germany
  • Dr. Elsmarieke van de Giessen – Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam/Netherlands

 

Suggested readings

  • Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Pappas V, Thies WH; Alzheimer’s Association; Society of Nuclear Medicine and Molecular Imaging; Amyloid Imaging Taskforce. Alzheimers Dement. 2013 Jan;9(1):e-1-16.
  • SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0.  Minoshima S, Drzezga AE, Barthel H, Bohnen N, Djekidel M, Lewis DH, Mathis CA, McConathy J, Nordberg A, Sabri O, Seibyl JP, Stokes MK, Van Laere K. J Nucl Med. 2016 Aug;57(8):1316-22
  • Yes we can analyse amyloid images – Now What? Barthel H, Seibyl J, Sabri O. Eur J Nucl Med Mol Imaging. 2017 May;44(5):822-824.
  • Proven validity and management impact of amyloid imaging in Alzheimer’s disease-repetita juvant. Barthel H, Arbizu J, Drzezga A, Garibotto V, Lammertsma AA, Morbelli S; EANM Neuroimaging Committee. Eur J Nucl Med Mol Imaging. 2020 Mar 4. doi: 10.1007/s00259-020-04742-w


PSMA Imaging in Advanced Prostate Cancer. From PET to PSMA Radio-Ligand Therapy

September 11, 2020 – 12:00 (CEST)

Speaker: Benedikt Feuerecker
Moderators: Francesco Ceci
Patrick Pilkington
Target audience: Nuclear Medicine Physicians, urologist, radiation oncologist, oncologist, residents

 

Content

In this live webinar we will discuss the role of PSMA PET imaging in advanced prostate cancer. More in detail this lecture will give recommendations regarding the proper selection of patients suitable for PSMA based radioligand therapy.

 

Learning objectives

  • To understand how to interpret PSMA PET scans in advanced metastatic patients
  • To understand which PET parameters should be taken into consideration prior to radio-ligand therapy
  • To understand possible sources of error (e.g. PSMA negative lesions or missmatch between PSMA and FDG PET)

 

Faculty

  • Dr. Benedikt Feuerecker – Department of Nuclear Medicine, Klinikum rechts der Isar, Munich/Germany
  • Francesco Ceci MD PhD – Assistant Professor, University of Turin/Italy
  • Dr. Patrick Pilkington – Department of Nuclear Medicine, Hospital Universitario 12 de Octubre, Madrid/Spain

 

Suggested readings

  • Kratochwil C, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46(12):2536‐2544.
  • Hofman MS, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825‐833.
  • Kratochwil C, Haberkorn U, Giesel FL. Radionuclide Therapy of Metastatic Prostate Cancer. Semin Nucl Med. 2019;49(4):313‐325.
  • Fendler WP, et al. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019;25(24):7448‐7454. doi:10.1158/1078-0432.CCR-19-1050


Nuclear Medicine Diagnostics and Monitoring in Large Vessel Vasculitis and Cardiac Amyloidosis

September 11, 2020 – 14:00 (CEST)

Speakers: Olivier Gheysens  
Riemer Slart
Moderator: Christoph Rischpler
Target audience: Nuclear medicine physicians, residents NM, imaging-cardiologists, imaging-rheumatologists

 

Content

Large vessel vasculitis (LVV) is a disease characterized by inflammation of the larger arteries with two main variants Takayasu arteritis (TA) and giant cell arteritis (GCA). Both entities differ in terms of age onset, ethnic distribution and affected vascular territories, but share overlap in the histopathology of inflammatory lesions. In addition, GCA belongs to a disease spectrum with polymyalgia rheumatica with both entities often present within the same patient. Nowadays, FDG-PET/CT plays a crucial role in the diagnosis of patients with LVV or the co-existence of LVV and PMR. It is important to early establish the diagnosis of LVV to timely initiate therapy in order to prevent late complications such as stenoses and aneurysms.  Since FDG-PET is a whole-body imaging technique, it provides information of the vessels involved in the disease process and may assist in the differential diagnosis between PMR and other rheumatological disorders such as elderly-onset rheumatoid arthritis based on the inflammatory patterns. In additon to diagnosis, there is emerging evidence that FDG-PET is a suitable modality to assess therapy efficacy which may be important to evaluate novel anti-inflammatory drugs. The introduction of PET/MR may allow simultaneous information on vessel wall inflammation and morphology, which may be advantageous for assessing cranial arteries, but this requires further investigations. Finally, novel tracer development e.g. targeting interleukins may also play a role in the future.

Cardiac amyloidosis (CA), commonly resulting from deposition of misfolded immunoglobulin light chain (AL) or transthyretin (ATTR) protein, is an underestimated cause of heart failure. ATTR has gained increasing attention in recent years and can be divided into a hereditary type (ATTRv) and a wild-type (ATTRwt). Accurate and early diagnosis of heart failure as a result of CA has major implications on prognosis and treatment, using echo and MRI in the first line. Molecular imaging with PET and SPECT nowadays play a critical role in the diagnosis, identification and distinction between ATTR and AL type CA. Bone scintigraphy is an important non-invasive tool to diagnose cardiac amyloidosis due to ATTR (either ATTRv or ATTRwt). Additionally, the innervation agent 123I-MIBG accumulates in vesicles in sympathetic nerve endings close to myocardial cells and the reduced uptake and increased loss reflects myocardial cell damage caused by amyloid. More specific PET-imaging tracers in amyloidosis selectively bind to β-amyloid plaques. Current and new treatments are targeted at reducing the production or stabilisation of the precursor protein or aiming at promoting amyloid removal and thereby aim to stop or slow down further accumulation of CA. Molecular imaging should be able to visualize regression of CA under these new treatment regimens, but data are lacking at this moment. For diagnostic considerations, specific target imaging using hybrid or multimodality techniques such as PET/MR definitely will play a role in the future.

 

Learning objectives 

  • Background information of large vessel vasculitis (LVV)/polymyalgia rheumatica (PMR) and cardiac amyloidosis (CA), including the different types, and it’s disease burden.
  • The role of non-invasive imaging in the diagnostic work-up of LVV and CA.
  • Details of FDG PET/CT in LVV/PMR and bone agent imaging in CA, including imaging protocol, scoring, and interpretation, using the new consensus recommendations.
  • Overview of novel PET imaging in CA. • New therapy approaches for managing patients with LVV/CA

 

Faculty

  • Olivier Gheysens, MD PhD – Department of Nuclear Medicine, Cliniques universitaires Saint-Luc – Brussels/Belgium
  • Riemer H.J.A. Start, MD PhD – Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen/Netherlands
  • Prof. Dr. Christoph Rischpler – Department of Nuclear Medicine, University of Duisburg – Essen/Germany

 

Suggested readings

  • doi: 10.1007/s12350-019-01760-6
  • doi: 10.1007/s12350-019-01761-5
  • doi: 10.1007/s00259-018-3973-8
  • EANM 2018 & 2019 CME LVV and CA


Nuclear Imaging Technology: Where we came from, where we are and where we are heading

October 22, 2020 – 11.00 am (CET)

Speakers: Ian Armstrong Stephan Nekolla
John Dickson Dimitris Visvikis
Moderator: Michel Koole

I.Armstrong

J.Dickson

M.Koole

S.Nekolla

D.Visvikis

Content

Nuclear medicine is a field, which is almost one century old and provides one the oldest integrated approached between diagnostic, therapy and physics. The development of the latter in terms of diagnostic imaging and therapy assessment is the topic of this webinar. In particular, this introduction of “digital” imaging systems created quite some buzz. This webinar provides information where we are coming from, critically reflects on the latest generation of devices and attempts an outlook where we are – or at least – where we could head.
For the PET domain, we give an overview of the development of PET hardware. Focussing in particular on the transition from PMTs to solid-state SiPM technology. This brings substantial improvements to Time of Flight performance, increasing the effective sensitivity of the system.
For the SPECT realm, we will describe the ‘digital’ semiconductor technologies that have been used and are being developed for SPECT applications. Comparisons will be made with traditional scintillation devices to help define if and where these technologies could be used in the future and where traditional analog systems will remain the default.”
So, in summary, as over the past couple of decades there seems to be a new system (in terms of design or multimodality) as well as major technological developments taking place every ten years.
Within this context the webinar will aim at providing a few hints concerning such potential technological evolutions within the current decade.

 

Learning objectives

The aim of this webinar is to provide information on the origins of nuclear medicine and its dedicated imaging hardware, the introduction of hybrid systems, their development cycles since then and finally a critical outlook.

 

Faculty

  • Ian Armstrong, MPhys, Msc, PhD – Central Manchester University Hospitals, Manchester/UK
  • John Dickson, PhD – University College London Hospitals, London/UK
  • Stephan Nekolla, PhD – Klinikum rechts der Isar, Munich/Germany
  • Dimitris Visvikis, PhD – National Institute of Health and Research (INSERM), Brest/France
  • Michel Koole, PhD – KU Leuven, Leuven/Belgium

 

Suggested readings

  • Hutton BF. The origins of SPECT and SPECT/CT. Eur J Nucl Med Mol Imaging. 2014 May;41 Suppl 1:S3-16. doi: 10.1007/s00259-013-2606-5Sensors for Positron Emission Tomography Applications.
  • Jiang W, Chalich Y, Deen MJ. Sensors for Positron Emission Tomography Applications ; Sensors (Basel). 2019 Nov 17;19(22):5019.
  • Paul Lecoq: Pushing the Limits in Time-of-Flight PET Imaging: https://ieeexplore.ieee.org/document/8049484
  • Suleman Surti et al. : Total Body PET: Why, How, What for? : https://ieeexplore.ieee.org/document/9056798


PET MPI: Tracers, Equipment, Protocols, Flow Quantification, Viability

October 29, 2020 – 11:00 (CET)

Speakers: Mark Lubberink
Roberto Sciagrà
Moderator: Christoph Rischpler
Target audience: Nuclear Physicians with access to a PET facility, willing to begin with cardiac PET.

Content

The course will describe the procedures in cardiac PET, including the execution of cardiac perfusion PET with flow quantification, gated perfusion PET, PET with FDG for viability detection, hybrid imaging with PET/CT or PET/MR.

 

Learning objectives

The aim of the course is to allow a first orientation in the multiple possibilities of PET in the field of cardiac imaging, with particular regard to the implementation of quantitative cardiac PET protocols.

 

Faculty

  • Mark Lubberink, PhD – Department of Surgical Sciences / Nuclear Medicine & PET, Uppsala University Hospital – Uppsala/Sweden
  • Prof. Dr. Roberto Sciagrà – Department of Biomedical, Experimental and Clinical Sciences, University of Florence – Florence/Italy
  • Prof. Dr. Christoph Rischpler – Department of Nuclear Medicine, University of Duisburg – Essen/Germany

 


Hybrid Imaging in Paediatrics: From Equipment to Clinical Application

December 9, 2020 – 13:00 CET 

 
Speakers: Lorenzo Biassoni
  Alessandra Zorz
Moderator: Pietro Zucchetta
Target audience: Medical specialists and physicians in-training (residents) with special interest in paediatric nuclear medicine and paediatric multimodality imaging
 

Content

The first webinar of the ESMIT Paediatrics Mini-series will refresh your knowledge on hybrid imaging equipment and will highlight the importance of the use of SPECT and SPECT/CT for musculoskeletal imaging in Paediatrics.
In terms of pathology the focus will be on the limping child, trauma, infection, inflammation and other benign bone & joint diseases.

Faculty

  • Lorenzo Biassoni – Great Ormond Street Hospital for Children NHS Foundation Trust, London/UK
  • Alessandra Zorz – Veneto Institute of Oncology IOV – IRCCS, Padova/Italy
  • Pietro Zucchetta – University Hospital, Padova/Italy


Multimodality Imaging in Paediatrics: Bone Malignancies and Nephro-Urologic Diseases

December 10, 2020 – 12:30 CET 

 
Speakers: Francesco Ceci
  Isabel Roca
Moderator: Diego De Palma
Target audience: Medical specialists and physicians in-training (residents) with special interest in paediatric nuclear medicine and paediatric multimodality imaging
 

Content

The second webinar of the ESMIT Paediatrics Mini-series will cover the use of PET/CT and PET/MR in Paediatric bone malignancy, as well as the role of multimodality imaging in the work-out of nephro-urological Paediatric diseases with a focus on childhood urinary tract infections, evaluation of the dilated urinary tract and other frequent congenital anomalies.

Faculty

  • Francesco Ceci – University of Turin, Turin/Italy
  • Diego De Palma – Ospedale di Circolo, Varese/Italy
  • Isabel Roca – Hospital Universitari Vall d’Hebron, Barcelona/Spain

 


Theranostics in Neuroblastoma

December 11, 2020 – 10:30 CET

 
Speakers: Arnoldo Piccardo
  Soňa Balogova
  Kateřina Táborská
Moderator: Paola Anna Erba
Target audience: Medical specialists and physicians in-training (residents) with special interest in paediatric nuclear medicine and paediatric multimodality imaging
 

Content

This webinar, the 3rd of the ESMIT Paediatrics Mini-series dedicated to the application of multimodality imaging in Paediatrics, will consolidate basic knowledge on Neuroblastoma, covering common imaging protocols with tips for patient preparation. In addition, knowledge will be provided on the selection of patients for treatment with iodine-131 MIBG as well as on the practical aspects related to the phase of treatment administration and patients’ follow-up.

Faculty

  • Soňa Balogova – Comenius University, Bratislava/Slovakia
  • Paola Anna Erba – University of Pisa Medical School, Pisa/Italy
  • Arnoldo Piccardo – Galliera Hospital, Genoa/Italy
  • Kateřina Táborská – Charles University and Motol University Hospital, Prague/Czech Republic

 

 

This website uses cookies. Learn more